{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-033847","form_type":"8-K","ticker":null,"cik":"0001567892","company_name":"Keenova Therapeutics plc","filed_at":"2026-05-12T10:41:58+00:00","discovered_at":"2026-05-12T10:45:00.358775+00:00","generated_at":"2026-05-12T10:45:40.938512+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Keenova reports Q1 net sales $468M, loss $114M; reaffirms FY guidance","bullets":["Acthar Gel net sales $170M (+47% YoY); XIAFLEX net sales $134M.","Loss from continuing ops $114M; adjusted EBITDA $174M.","Reaffirmed FY2026 guidance: net sales $1.94B-$2.00B, adj. EBITDA $730M-$760M.","Realized $23M in merger synergies in Q1; on track for $100M in 2026.","Pipeline: Phase 3 plantar fibromatosis topline expected July 2026; FDA EOP2 meeting for hammer toe June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033847","json":"https://secwatch.observer/filing/0001628280-26-033847.json","markdown":"https://secwatch.observer/filing/0001628280-26-033847.md","text":"https://secwatch.observer/filing/0001628280-26-033847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/0001628280-26-033847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/mnk-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T10:45:40.938512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f587bd4b105133c3c80aeac3beaf5c04e7e38acc","claim":"Keenova Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $468 million. Guidance reaffirmed.","evidence_excerpt":"Today at 8:00 a.m. ET First Quarter 2026 Highlights 3 • Acthar Gel net sales of $170 million • XIAFLEX net sales of $134 million • Net sales from continuing operations of $468 million • Loss from continuing operations of $114 million • Adjusted EBITDA from continuing operations of $174 million DUBLIN, May 12, 2026 – Keenova Therapeutics plc (“Keenova” or the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/0001628280-26-033847-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$468 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}